What happened with APYX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Most of Apyx Medical’s revenue comes from cosmetic-surgery equipment and single-use handpieces, with handpieces contributing a substantial share. Its Renuvion system uses radiofrequency energy and helium to deliver a plasma beam that cuts, coagulates or ablates soft tissue. AYON combines fat removal with Renuvion tissue contraction and other surgical functions. Physicians, cosmetic surgery offices and surgical centers buy primarily through the company’s direct sales force in the United States; distributors are the main route outside the country.
Equipment purchases and ongoing handpiece demand depend on doctors adopting the systems and patients choosing procedures. These cosmetic procedures are elective and patients pay for them without government or private health-insurance reimbursement, so demand depends on patients’ ability and willingness to spend. Medical-device clearances restrict the uses Apyx may promote, and new or expanded uses require regulatory clearance.
A smaller business develops and manufactures devices and accessories for other medical-device companies, including products supplied to Symmetry Surgical under a manufacturing agreement. Apyx also supports hospital surgeons using its J-Plasma technology in some international markets.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Apyx Medical’s results hinge on cosmetic-surgery procedure volumes and adoption of Renuvion and AYON, while privately held MicroAire Surgical Instruments also competes directly in liposuction.
InMode competes for aesthetic surgeons’ equipment spending with platforms that reduce fat and tighten skin using radio-frequency energy, against Apyx Medical’s Renuvion tissue-contraction and AYON body-contouring systems. Watch InMode’s sales of these platforms for signs of competition for the same surgeons’ purchases.
Bausch Health’s Solta Medical sells liposuction equipment that competes directly with Apyx Medical’s AYON for cosmetic-surgery customers. Bausch Health also sells pharmaceuticals and eye-health products, so its Solta Medical aesthetic-device revenue is more relevant to this rivalry than its group sales.
Bausch Health Companies Inc earningsBHC
Solta Medical’s liposuction-equipment sales in Bausch Health’s report will show how cosmetic-surgery customers are buying equipment that competes directly with Apyx Medical’s AYON.
Look at Solta Medical’s liposuction-equipment sales, not Bausch Health’s total sales: the group also sells pharmaceuticals and eye-health products. Stronger Solta sales would show that customers are buying equipment that competes with AYON for cosmetic-surgery spending, but would not prove AYON lost orders. Weaker sales would point to less momentum for this competing equipment, not prove demand for AYON is stronger. The report helps show whether Solta’s competing category is drawing customer purchases.
Fed Interest Rate Decision
Apyx Medical’s floating-rate term loan means policy rates can change its interest bill and the cash left to support sales of Renuvion, AYON and their handpieces.
Expected4.0%Last release4.0%
If it comes in above expectations
If rates rise, Apyx Medical pays more interest on its floating-rate loan, leaving less cash for selling and supporting its surgical systems and handpieces.
If it comes in below expectations
If rates fall, Apyx Medical pays less interest on its floating-rate loan, leaving more cash for selling and supporting its surgical systems and handpieces.
Apyx Medical Corporation earningsThis company
Apyx Medical’s report will show whether AYON can keep its Surgical Aesthetics business growing against the 2025 decline in single-use handpiece volume.
Read Surgical Aesthetics sales alongside gross margin, then check operating cash use and OEM sales. Growing Surgical Aesthetics sales with a steady margin and less cash use would suggest AYON’s added revenue is building useful scale; weak sales, margin pressure or continued cash use alongside shrinking OEM revenue would show that new-product sales are not yet easing the strain on the business and its funding needs. The combination shows whether AYON is becoming a meaningful growth engine.
Retail Sales MoM (Oct)
Retail sales track consumer spending, which can affect patients’ willingness and ability to pay out of pocket for elective cosmetic procedures using Apyx Medical’s Renuvion and AYON systems and handpieces.
If consumers are spending more, patients may be more willing and able to pay for elective cosmetic procedures using Apyx Medical’s systems; if spending is weakening, demand for those systems and handpieces may come under pressure.
